Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$9.41 +2.8%	$8.27	$2.99 ▼ $10.28	$1.42B	1.75	1.58 million shs	771,555 shs
AUPH Aurinia Pharmaceuticals	$8.01 +0.3%	$8.00	$5.11 ▼ $10.67	$1.08B	1.16	1.33 million shs	445,007 shs
IOVA Iovance Biotherapeutics	$1.83 +4.6%	$2.87	$1.64 ▼ $12.51	$609.43M	1.06	8.69 million shs	4.27 million shs
TKNO Alpha Teknova	$5.88 +1.3%	$5.95	$1.16 ▼ $10.37	$311.56M	0.5	392,926 shs	86,850 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	+0.11%	+0.66%	+17.76%	+12.13%	+150.68%
AUPH Aurinia Pharmaceuticals	-2.09%	-4.32%	-0.25%	+5.70%	+50.85%
IOVA Iovance Biotherapeutics	+1.16%	-0.28%	-51.52%	-66.73%	-81.96%
TKNO Alpha Teknova	-1.19%	-10.77%	-13.56%	-11.99%	+226.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.1918 of 5 stars	1.4	2.0	4.2	4.2	2.5	0.6
AUPH Aurinia Pharmaceuticals	3.3847 of 5 stars	3.5	2.0	0.0	4.1	1.7	1.9
IOVA Iovance Biotherapeutics	4.6644 of 5 stars	4.3	1.0	4.2	2.8	4.2	1.3
TKNO Alpha Teknova	1.819 of 5 stars	3.5	1.0	0.0	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.83	Moderate Buy	$9.83	4.51% Upside
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	43.66% Upside
IOVA Iovance Biotherapeutics	2.50	Moderate Buy	$13.30	626.38% Upside
TKNO Alpha Teknova	3.00	Buy	$8.50	44.68% Upside

Current Analyst Ratings Breakdown

Latest TKNO, AUPH, ADPT, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$17.00 ➝ $2.00
5/12/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $8.00
5/12/2025	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $10.00
5/12/2025	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/12/2025	IOVA Iovance Biotherapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	IOVA Iovance Biotherapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
5/9/2025	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/9/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $20.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	7.54	N/A	N/A	$1.37 per share	6.87
AUPH Aurinia Pharmaceuticals	$247.30M	4.37	N/A	N/A	$2.63 per share	3.04
IOVA Iovance Biotherapeutics	$212.68M	2.87	N/A	N/A	$2.28 per share	0.80
TKNO Alpha Teknova	$38.25M	8.21	N/A	N/A	$2.21 per share	2.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-89.12%	-64.65%	-26.45%	8/7/2025 (Estimated)
AUPH Aurinia Pharmaceuticals	-$78.02M	$0.28	N/A	14.29	N/A	-10.23%	-4.41%	-3.07%	8/7/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$444.04M	-$1.24	N/A	N/A	N/A	-451.25%	-58.43%	-45.48%	8/14/2025 (Estimated)
TKNO Alpha Teknova	-$36.78M	-$0.48	N/A	N/A	N/A	-87.17%	-35.30%	-24.52%	N/A

Latest TKNO, AUPH, ADPT, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/8/2025	Q1 2025	TKNO Alpha Teknova	-$0.11	-$0.09	+$0.02	-$0.09	$9.41 million	$9.60 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
3/4/2025	Q4 2024	TKNO Alpha Teknova	N/A	-$0.11	N/A	-$0.11	$9.10 million	$9.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.89	2.81
AUPH Aurinia Pharmaceuticals	0.17	5.60	5.11
IOVA Iovance Biotherapeutics	N/A	4.22	3.90
TKNO Alpha Teknova	0.12	4.73	3.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
AUPH Aurinia Pharmaceuticals	36.83%
IOVA Iovance Biotherapeutics	77.03%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
AUPH Aurinia Pharmaceuticals	12.20%
IOVA Iovance Biotherapeutics	12.10%
TKNO Alpha Teknova	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	138.43 million	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	137.02 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	267.90 million	Optionable
TKNO Alpha Teknova	240	53.44 million	45.21 million	Not Optionable

TKNO, AUPH, ADPT, and IOVA Headlines

Recent News About These Companies

OMERS ADMINISTRATION Corp Makes New Investment in Alpha Teknova, Inc. (NASDAQ:TKNO)

May 22, 2025 | marketbeat.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Stake Reduced by Schonfeld Strategic Advisors LLC

May 17, 2025 | marketbeat.com

Susquehanna International Group LLP Buys 172,828 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

May 13, 2025 | marketbeat.com

Alpha Teknova (NASDAQ:TKNO) Posts Earnings Results

May 12, 2025 | marketbeat.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Raymond James Financial Inc. Invests $716,000 in Alpha Teknova, Inc. (NASDAQ:TKNO)

May 9, 2025 | marketbeat.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

683 Capital Management LLC Acquires New Shares in Alpha Teknova, Inc. (NASDAQ:TKNO)

May 4, 2025 | marketbeat.com

65,036 Shares in Alpha Teknova, Inc. (NASDAQ:TKNO) Purchased by Apollo Management Holdings L.P.

May 2, 2025 | marketbeat.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.com

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

BTIG Reaffirms Their Hold Rating on Alpha Teknova (TKNO)

March 6, 2025 | markets.businessinsider.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TKNO, AUPH, ADPT, and IOVA Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$9.41 +0.26 (+2.83%)

As of 01:21 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.01 +0.03 (+0.31%)

As of 01:22 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Iovance Biotherapeutics NASDAQ:IOVA

$1.83 +0.08 (+4.63%)

As of 01:22 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Alpha Teknova NASDAQ:TKNO

$5.88 +0.08 (+1.29%)

As of 01:22 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time